We discuss screening in this third post on structural biology and structure-based drug design. Compound screening is central to all drug design strategies discussed earlier. The quality of the compounds we identify in this process will be crucial for the discovery project.
Which strategy to choose when planning a drug discovery project? Maybe structure-based design, ligand-based design, or de novo design? These questions are discussed in our series on structure-based drug design in this second post.
The contribution of structural biology to the field of drug discovery is enormous. However, applying structural biology methods requires many different skills and often a lot of experience. A structural biology services company is usually built around a technology platform that brings together people with the experience and skills required to run a drug discovery project.
A new consortium aimed at leveraging the partner's technology platforms for accelerating structure-based drug discovery targeting a “weak spot” in the Sars-CoV-2 virus replication machinery, the NSP10 protein.